Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 457 to 464 of 464 entries
Sorted by: Best Match Show Resources per page
Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.

Canadian journal of diabetes

Majdpour D, Tsoukas MA, Yale JF, El Fathi A, Rutkowski J, Rene J, Garfield N, Legault L, Haidar A.
PMID: 33888413
Can J Diabetes. 2021 Feb 20; doi: 10.1016/j.jcjd.2021.02.002. Epub 2021 Feb 20.

OBJECTIVES: A fully automated insulin-pramlintide-glucagon artificial pancreas that alleviates the burden of carbohydrate counting without degrading glycemic control was iteratively enhanced until convergence through pilot experiments on adults with type 1 diabetes.METHODS: Nine participants (age, 37±13 years; glycated hemoglobin,...

Cite
Majdpour D, Tsoukas MA, Yale JF, et al. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments. Can J Diabetes. 2021;doi: 10.1016/j.jcjd.2021.02.002.
Majdpour, D., Tsoukas, M. A., Yale, J. F., El Fathi, A., Rutkowski, J., Rene, J., Garfield, N., Legault, L., & Haidar, A. (2021). Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments. Canadian journal of diabetes, . https://doi.org/10.1016/j.jcjd.2021.02.002
Majdpour, Dorsa, et al. "Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments." Canadian journal of diabetes vol. (2021). doi: https://doi.org/10.1016/j.jcjd.2021.02.002
Majdpour D, Tsoukas MA, Yale JF, El Fathi A, Rutkowski J, Rene J, Garfield N, Legault L, Haidar A. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments. Can J Diabetes. 2021 Feb 20; doi: 10.1016/j.jcjd.2021.02.002. Epub 2021 Feb 20. PMID: 33888413.
Copy Download .nbib Format: NLM
Neural Injury and Repair in a Novel Neonatal Mouse Model of Listeria Monocytogenes Meningoencephalitis.

Journal of neuropathology and experimental neurology

Seele J, Ballüer M, Tauber SC, Bunkowski S, Schulz K, Stadelmann C, Beineke A, Pägelow D, Fulde M, Nau R.
PMID: 34486672
J Neuropathol Exp Neurol. 2021 Sep 27;80(9):861-867. doi: 10.1093/jnen/nlab079.

To improve the therapy of neonatal central nervous system infections, well-characterized animal models are urgently needed. The present study analyzes neuropathological alterations with particular focus on neural injury and repair in brains of neonatal mice with Listeria monocytogenes (LM)...

Cite
Seele J, Ballüer M, Tauber SC, et al. Neural Injury and Repair in a Novel Neonatal Mouse Model of Listeria Monocytogenes Meningoencephalitis. J Neuropathol Exp Neurol. 2021;80(9):861-867doi: 10.1093/jnen/nlab079.
Seele, J., Ballüer, M., Tauber, S. C., Bunkowski, S., Schulz, K., Stadelmann, C., Beineke, A., Pägelow, D., Fulde, M., & Nau, R. (2021). Neural Injury and Repair in a Novel Neonatal Mouse Model of Listeria Monocytogenes Meningoencephalitis. Journal of neuropathology and experimental neurology, 80(9), 861-867. https://doi.org/10.1093/jnen/nlab079
Seele, Jana, et al. "Neural Injury and Repair in a Novel Neonatal Mouse Model of Listeria Monocytogenes Meningoencephalitis." Journal of neuropathology and experimental neurology vol. 80,9 (2021): 861-867. doi: https://doi.org/10.1093/jnen/nlab079
Seele J, Ballüer M, Tauber SC, Bunkowski S, Schulz K, Stadelmann C, Beineke A, Pägelow D, Fulde M, Nau R. Neural Injury and Repair in a Novel Neonatal Mouse Model of Listeria Monocytogenes Meningoencephalitis. J Neuropathol Exp Neurol. 2021 Sep 27;80(9):861-867. doi: 10.1093/jnen/nlab079. PMID: 34486672.
Copy Download .nbib Format: NLM
Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment.

Hepatology (Baltimore, Md.)

Flores Carvalho M, Mueller M, Muiesan P, Dutkowski P, Schlegel A.
PMID: 33942337
Hepatology. 2021 Oct;74(4):2309-2310. doi: 10.1002/hep.31878. Epub 2021 Aug 21.

No abstract available.

Cite
Flores Carvalho M, Mueller M, Muiesan P, et al. Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment. Hepatology. 2021;74(4):2309-2310doi: 10.1002/hep.31878.
Flores Carvalho, M., Mueller, M., Muiesan, P., Dutkowski, P., & Schlegel, A. (2021). Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment. Hepatology (Baltimore, Md.), 74(4), 2309-2310. https://doi.org/10.1002/hep.31878
Flores Carvalho, Mauricio, et al. "Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 2309-2310. doi: https://doi.org/10.1002/hep.31878
Flores Carvalho M, Mueller M, Muiesan P, Dutkowski P, Schlegel A. Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment. Hepatology. 2021 Oct;74(4):2309-2310. doi: 10.1002/hep.31878. Epub 2021 Aug 21. PMID: 33942337.
Copy Download .nbib Format: NLM
The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas.

Cancers

Spałek MJ, Borkowska AM, Telejko M, Wągrodzki M, Niebyłowska D, Uzar A, Białobrzeska M, Rutkowski P.
PMID: 33809547
Cancers (Basel). 2021 Mar 16;13(6). doi: 10.3390/cancers13061332.

INTRODUCTION: Management of marginally resectable or unresectable soft tissue sarcomas (STS) in patients who are not candidates for neoadjuvant chemotherapy due to chemoresistant pathology or contraindications remains a challenge. Therefore, in these indications, we aimed to investigate a feasibility...

Cite
Spałek MJ, Borkowska AM, Telejko M, et al. The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061332.
Spałek, M. J., Borkowska, A. M., Telejko, M., Wągrodzki, M., Niebyłowska, D., Uzar, A., Białobrzeska, M., & Rutkowski, P. (2021). The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. Cancers, 13(6), . https://doi.org/10.3390/cancers13061332
Spałek, Mateusz Jacek, et al. "The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061332
Spałek MJ, Borkowska AM, Telejko M, Wągrodzki M, Niebyłowska D, Uzar A, Białobrzeska M, Rutkowski P. The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. Cancers (Basel). 2021 Mar 16;13(6). doi: 10.3390/cancers13061332. PMID: 33809547; PMCID: PMC8000962.
Copy Download .nbib Format: NLM
TP53 in Biology and Treatment of Osteosarcoma.

Cancers

Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, Stasinska A, Rutkowski P, Grieb P.
PMID: 34503094
Cancers (Basel). 2021 Aug 25;13(17). doi: 10.3390/cancers13174284.

The

Cite
Synoradzki KJ, Bartnik E, Czarnecka AM, et al. TP53 in Biology and Treatment of Osteosarcoma. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174284.
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P., & Grieb, P. (2021). TP53 in Biology and Treatment of Osteosarcoma. Cancers, 13(17), . https://doi.org/10.3390/cancers13174284
Synoradzki, Kamil Jozef, et al. "TP53 in Biology and Treatment of Osteosarcoma." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174284
Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, Stasinska A, Rutkowski P, Grieb P. TP53 in Biology and Treatment of Osteosarcoma. Cancers (Basel). 2021 Aug 25;13(17). doi: 10.3390/cancers13174284. PMID: 34503094; PMCID: PMC8428337.
Copy Download .nbib Format: NLM
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF .

Cancers

Czarnecka AM, Ostaszewski K, Borkowska A, Szumera-Ciećkiewicz A, Kozak K, Świtaj T, Rogala P, Kalinowska I, Koseła-Paterczyk H, Zaborowski K, Teterycz P, Tysarowski A, Makuła D, Rutkowski P.
PMID: 35008274
Cancers (Basel). 2021 Dec 27;14(1). doi: 10.3390/cancers14010110.

Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery and adjuvant treatment as it is for sarcoma, breast, rectal, esophageal, or gastric cancers. Patients with locoregional...

Cite
Czarnecka AM, Ostaszewski K, Borkowska A, et al. Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF . Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010110.
Czarnecka, A. M., Ostaszewski, K., Borkowska, A., Szumera-Ciećkiewicz, A., Kozak, K., Świtaj, T., Rogala, P., Kalinowska, I., Koseła-Paterczyk, H., Zaborowski, K., Teterycz, P., Tysarowski, A., Makuła, D., & Rutkowski, P. (2021). Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF . Cancers, 14(1), . https://doi.org/10.3390/cancers14010110
Czarnecka, Anna M, et al. "Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF ." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010110
Czarnecka AM, Ostaszewski K, Borkowska A, Szumera-Ciećkiewicz A, Kozak K, Świtaj T, Rogala P, Kalinowska I, Koseła-Paterczyk H, Zaborowski K, Teterycz P, Tysarowski A, Makuła D, Rutkowski P. Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF . Cancers (Basel). 2021 Dec 27;14(1). doi: 10.3390/cancers14010110. PMID: 35008274.
Copy Download .nbib Format: NLM
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial.

Cancers

Lee CJ, Modave E, Boeckx B, Stacchiotti S, Rutkowski P, Blay JY, Debiec-Rychter M, Sciot R, Lambrechts D, Wozniak A, Schöffski P.
PMID: 34885165
Cancers (Basel). 2021 Dec 01;13(23). doi: 10.3390/cancers13236057.

Clear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to

Cite
Lee CJ, Modave E, Boeckx B, et al. Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236057.
Lee, C. J., Modave, E., Boeckx, B., Stacchiotti, S., Rutkowski, P., Blay, J. Y., Debiec-Rychter, M., Sciot, R., Lambrechts, D., Wozniak, A., & Schöffski, P. (2021). Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. Cancers, 13(23), . https://doi.org/10.3390/cancers13236057
Lee, Che-Jui, et al. "Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236057
Lee CJ, Modave E, Boeckx B, Stacchiotti S, Rutkowski P, Blay JY, Debiec-Rychter M, Sciot R, Lambrechts D, Wozniak A, Schöffski P. Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. Cancers (Basel). 2021 Dec 01;13(23). doi: 10.3390/cancers13236057. PMID: 34885165; PMCID: PMC8657105.
Copy Download .nbib Format: NLM
Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber DC, Frick S, Gurtner K, Matuschek C, Harrabi SB, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber NU, Obrecht D, Rutkowski S, Timmermann B, Kortmann RD.
PMID: 34351451
Strahlenther Onkol. 2021 Aug 05; doi: 10.1007/s00066-021-01822-0. Epub 2021 Aug 05.

PURPOSE: In Germany, Austria, and Switzerland, pretreatment radiotherapy quality control (RT-QC) for tumor bed boost (TB) in non-metastatic medulloblastoma (MB) was not mandatory but was recommended for patients enrolled in the SIOP PNET5 MB trial between 2014 and 2018....

Cite
Dietzsch S, Braesigk A, Seidel C, et al. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlenther Onkol. 2021;doi: 10.1007/s00066-021-01822-0.
Dietzsch, S., Braesigk, A., Seidel, C., Remmele, J., Kitzing, R., Schlender, T., Mynarek, M., Geismar, D., Jablonska, K., Schwarz, R., Pazos, M., Weber, D. C., Frick, S., Gurtner, K., Matuschek, C., Harrabi, S. B., Glück, A., Lewitzki, V., Dieckmann, K., Benesch, M., Gerber, N. U., Obrecht, D., Rutkowski, S., Timmermann, B., & Kortmann, R. D. (2021). Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], . https://doi.org/10.1007/s00066-021-01822-0
Dietzsch, Stefan, et al. "Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial." Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] vol. (2021). doi: https://doi.org/10.1007/s00066-021-01822-0
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber DC, Frick S, Gurtner K, Matuschek C, Harrabi SB, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber NU, Obrecht D, Rutkowski S, Timmermann B, Kortmann RD. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlenther Onkol. 2021 Aug 05; doi: 10.1007/s00066-021-01822-0. Epub 2021 Aug 05. PMID: 34351451.
Copy Download .nbib Format: NLM
Showing 457 to 464 of 464 entries